Scandinavian ChemoTech

The patent refers to D-EECT, which was the development name for the technological platform that is the basis for ChemoTech's tumor-specific electroporation technology (TSE), which has been shown in clinical publications to have both efficacy and safety as well as potential in the treatment of various forms of cancer.

The technology has been documented to be able to create an effective treatment, which also produces immunological effects, with only 5-10 percent of the previous maximum doses of cytostatics. Today, TSE has been successfully used for the treatment of head and neck, breast, skin, and pancreatic cancer in humans as well as for several types of tumors in dogs and cats. In the past year, TSE has also been used with great success for the treatment of various tumors in horses, including sarcoids.

"It feels good that we can get through patent applications in our strategic markets without major problems, which creates favorable conditions for future market expansions and partnerships," says Mohan Frick, CEO of Scandinavian ChemoTech.

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.